Agilent receives CE Mark for new companion diagnostic tool for cancer

Agilent Technologies has received European CE Mark approval for a new companion diagnostic test for personalised cancer treatment.

The PD-L1 IHC 22C3 pharmDx assay is designed to reveal whether a patient with advanced non-small cell lung cancer (NSCLC) is likely to respond to treatment with Merck Sharp and Dohme's anti-PD-1 therapy Keytruda.

Agilent produced the test in partnership with Merck to help establish whether or not individual patients' tumours express PD-L1.

Keytruda is approved for the treatment of locally advanced or metastatic NSCLC among patients who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK-positive mutations should also have received treatment for these mutations prior to receiving the drug.

Jacob Thaysen, president of Agilent's diagnostics and genomics group, said: "Because individuals often respond differently to the same treatment, scientists have been putting more emphasis on personalised medicine, which is where PD-L1 IHC 22C3 pharmDx comes into play."

This comes after the firm completed the asset acquisition of iLab Solutions earlier this month, strengthening its offering of laboratory management software.

With over 20 years of experience within the science market, we at Zenopa have the knowledge skill and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.